Speaker illustration

Doctor Dennis Kannenkeril

University Hospital Erlangen, Erlangen (Germany)

Member of:

European Society of Cardiology

PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease

Event: ESC Congress 2022

Topic: Lipid-Lowering Agents

Session: Lipid-lowering by PCSK9 modulation: what’s new?

Thumbnail

This platform is supported by

logo Novo Nordisk